公开(公告)号：US20240369560A1

公开(公告)日：2024-11-07

申请号：US18580412

申请日：2022-07-21

Applicant: Mercy Bioanalytics, Inc.

Inventor： Joseph Charles Sedlak ,  Emily Susan Winn-Deen ,  Daniel Gusenleitner ,  Anthony David Couvillion ,  Laura Teresa Bortolin ,  Daniel Parker Salem ,  Kelly Biette

IPC: G01N33/574 ,  G01N27/74

Abstract: The present disclosure in one aspect provides technologies for detection of pancreatic cancer, e.g., early detection of pancreatic cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to pancreatic cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

公开(公告)号：US20240344139A1

公开(公告)日：2024-10-17

申请号：US18580444

申请日：2022-07-21

Applicant: Mercy Bioanalytics, Inc.

Inventor： Joseph Charles Sedlak ,  Emily Susan Winn-Deen ,  Daniel Gusenleitner ,  Anthony David Couvillon ,  Laura Teresa Bortolin ,  Daniel Parker Salem ,  Kelly Biette ,  Sanchari Banerjee

IPC: C12Q1/6886 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  G01N33/57419 ,  C12Q2600/158

Abstract: The present disclosure in one aspect provides technologies for detection of colorectal cancer, e.g., early detection of colorectal cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to colorectal cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

公开(公告)号：US20240011993A1

公开(公告)日：2024-01-11

申请号：US18015051

申请日：2021-07-08

Applicant: Mercy BioAnalytics, Inc.

Inventor： Joseph Charles Sedlak ,  Laura Teresa Bortolin ,  Daniel Parker Salem ,  Emily Susan Winn-Deen ,  Daniel Gusenleitner ,  Anthony David Couvillon

IPC: G01N33/574 ,  C12Q1/6886

CPC classification number: G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/158

Abstract: The present disclosure in one aspect provides technologies for detection of lung cancer, e.g, early detection of lung cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to lung cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g, by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

公开(公告)号：US20240369558A1

公开(公告)日：2024-11-07

申请号：US18580427

申请日：2022-07-21

Applicant: Mercy Bioanalytics, Inc.

Inventor： Joseph Charles Sedlak ,  Emily Susan Winn-Deen ,  Daniel Gusenleitner ,  Anthony David Couvillon ,  laura Teresa Bortolin ,  Daniel Parker Salem ,  Kelly Biette ,  Ibukunoluwapo O. Zabroski

IPC: G01N33/574 ,  C12Q1/6886

Abstract: The present disclosure in one aspect provides technologies for detection of breast cancer, e.g., early detection of breast cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to breast cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.